Showing 1,441 - 1,460 results of 1,775 for search '"Therapy"', query time: 0.07s Refine Results
  1. 1441
  2. 1442

    Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer by Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi

    Published 2025-02-01
    “…Luminal-like tumors primarily benefit from a first line treatment strategy combining endocrine therapy and cyclin-dependent kinase 4/6 inhibitors. …”
    Get full text
    Article
  3. 1443

    Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta by Jennifer Walsh, Catriona Keerie, Stuart H Ralston, Christopher J Weir, Muhammad K Javaid, WAYNE LAM, Bente L Langdahl, Jannie D Hald, Patricia Osborne

    Published 2023-11-01
    “…The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid trial will determine if therapy with teriparatide (TPTD) followed by zoledronic acid (ZA) can reduce the risk of clinical fractures in OI.Methods and analysis Individuals aged ≥18 years with a clinical diagnosis of OI are eligible to take part. …”
    Get full text
    Article
  4. 1444

    Feasibility of home-based transcranial direct current stimulation combined with personalized word retrieval for improving naming in primary progressive aphasia by Allan George, Eric McConathey, Amy Vogel-Eyny, Elizabeth Galletta, Giuseppina Pilloni, Leigh Charvet

    Published 2025-02-01
    “…Background/ObjectivesPrimary progressive aphasia (PPA) is managed with speech-language therapy (SLT) to slow language decline. Pairing transcranial direct current stimulation (tDCS) with SLT can enhance its effects. …”
    Get full text
    Article
  5. 1445

    Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis by Daiki Nakashima, MD, Tsuguhisa Nakayama, MD, PhD, Shunsuke Minagawa, MD, PhD, Tetsuya Adachi, MD, PhD, Chieko Mitsuyama, MD, Yoko Shida, MD, Tsuneya Nakajima, MD, PhD, Shin-ichi Haruna, MD, PhD, Yoshinori Matsuwaki, MD, PhD

    Published 2025-05-01
    “…Nasal polyps had disappeared in 91 patients (85.9%) at 12 months, and there was improvement in all end points; 104 patients (97.2%) were able to eliminate systemic corticosteroid therapy. In the multivariate analysis, male sex was significantly associated with patients who did not show an improvement to 0 in the NPS and computed tomography score (odds ratios: 7.58 and 2.45; P = .01 and P = .04, respectively). …”
    Get full text
    Article
  6. 1446
  7. 1447

    Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle by Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz, Erik S. Knudsen

    Published 2025-02-01
    “…Abstract Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2 and undergo G1 cell cycle arrest following CDK2 inhibition. …”
    Get full text
    Article
  8. 1448

    USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation by Na Shao, Lei Xi, Yangfan Lv, Muhammad Idris, Lin Zhang, Ya Cao, Jingyi Xiang, Xi Xu, Belinda X. Ong, Qiongyi Zhang, Xu Peng, Xiaoyan Yue, Feng Xu, Chungang Liu

    Published 2025-02-01
    “…Combining USP5 inhibition with anti-PD-L1 therapy enhances anti-tumor immunity, suggesting USP5 as a potential biomarker for patient stratification. …”
    Get full text
    Article
  9. 1449

    Role of Inflammation and Motility Disorders in the Development, Course and Consequences of Functional Gastrointestinal and Biliary Tract Diseases (Literature Review and Expert Pane... by V. T. Ivashkin, D. S. Bordin, T. L. Lapina, M. A. Livzan, A. V. Okhlobystin, E. A. Poluektova, A. S. Trukhmanov, Yu. P. Uspenskiy, Yu. O. Shulpekova

    Published 2024-10-01
    “…Aim: to present the results of the Expert Panel with a discussion of modern concepts of the pathogenesis of functional gastrointestinal diseases and the possibilities of multitarget therapy with trimebutine.   Key points. Low-grade inflammation can be considered as a morphological substrate of functional diseases with an increase in activated mastocytes and eosinophils, T-helpers 2 and T-helpers 17 in the gastrointestinal mucosa. …”
    Get full text
    Article
  10. 1450

    Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C by M. V. Mayevskaya, O. O. Znoyko, E. A. Klimova, S. L. Maximov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya

    Published 2013-03-01
    “…Comparative analysis of virologic response rate after 4th and 12th weeks of the therapy and biochemical response did not show any statistically significant differences between the groups. …”
    Get full text
    Article
  11. 1451

    Outcomes of Surgical Treatment of Multiple Primary Colorectal and Prostate Cancer by I. S. Ignatov, V. V. Balaban, E. A. Bezrukov, A. V. Nikishina, M. He, P. V. Tsarkov

    Published 2025-02-01
    “…A clinician should be alert to multiple primary colorectal and prostate cancer. The first stage of therapy for the synchronous variant should be surgical treatment of colorectal cancer. …”
    Get full text
    Article
  12. 1452
  13. 1453
  14. 1454

    Endothelial AGGF1 promotes retinal angiogenesis by coordinating TNFSF12/FN14 signalling by Ying Cheng, Man Zhang, Chenguang Li, Long Su, Lingli Fu, Shi Wu, Chaofei Xu, Bei Sun, Liming Chen

    Published 2025-02-01
    “…Overall, we elucidate the mechanism underlying pathological retinal angiogenesis involved in endothelial AGGF1-dependent events and highlight a therapy for the effective treatment of ischaemic retinopathy.…”
    Get full text
    Article
  15. 1455

    Evaluation of the effect of Irritrol as final irrigant against Staphylococcus epidermidis: an in Vitro Study. by Hezha Saadi Hassan, Diyar Khalid Bakr

    Published 2022-02-01
    “…Staphylococcus epidermidis is one of the most isolated or detected species from oral infections, including marginal periodontitis, infected root canals, peri‐radicular, peri‐implantitis, and also detected in cases of failed endodontic therapy. In order to prevent endodontic treatment, failure irrigation is mandatory for the effective removal of smear, pulp tissue, smear layer,and microorganisms. …”
    Get full text
    Article
  16. 1456

    Developing a medication-safety self-assessment tool for rural primary care units - a case from Finnish Lapland by Päivi Sova, Ercan Celikkayalar, Sami Sneck, Anna-Riia Holmström

    Published 2025-02-01
    “…Abstract Background In rural areas, primary care faces several challenges, and medication therapy is one of the most complex processes in primary care. …”
    Get full text
    Article
  17. 1457

    Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD by Andrew D Schreiner, William P Moran, Jingwen Zhang, Patrick D Mauldin, Justin Marsden, Mulugeta Gebregziabher, Chelsey A Petz, David G Koch, Chloe Bays

    Published 2024-07-01
    “…We developed Cox regression models for the time to a high-risk FIB-4 score with statin therapy as the primary covariate and adjusting for baseline fibrosis risk, demographic and comorbidity variables.Results The cohort of 1238 patients with MASLD was followed for a mean of 3.3 years, with 47% of patients receiving a prescription for a statin, and 18% of patients progressing to a high-risk FIB-4. …”
    Get full text
    Article
  18. 1458

    Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population by Dingwei Dai, Ajay Sharma, Amy L. Phillips, Carroline Lobo

    Published 2022-11-01
    “…Eligibility criteria were (1) at least 3 MS-related inpatient/outpatient (ICD-10-CM: G35), or disease-modifying therapy claims within 1 year (date of first claim = index date); (2) Aetna commercial health plan or Medicare Advantage medical and pharmacy benefits at least 12 months pre-/post-index; and (3) age 18 and older. …”
    Get full text
    Article
  19. 1459

    Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and... by Yulin Shi, Yang Yu, Jiahan Zhao, Linan Huang, Qingyang Wang, Qi Sun, Lijuan Liu, Changgang Sun

    Published 2025-02-01
    “…Abstract Low immune infiltration is closely associated with poor clinical results and an unfavorable response to therapy in triple-negative breast cancer (TNBC). T-cell exhaustion (TEX) is a significant risk factor for tumor immunosuppression and invasion. …”
    Get full text
    Article
  20. 1460

    Management of volume load for patients undergoing hemodialysis via WeChat and home monitoring in China: a protocol for a cluster-randomized trial by Xiaocui Wang, Bonan Yan, Shipeng Zhang, Yuanke Zhou, Qinxiu Zhang, Xueying Li

    Published 2025-02-01
    “…Abstract Background Volume overload is a major mortality risk in hemodialysis (HD) patients. Drug therapy and conventional dialysis limitations underscore the importance of managing volume load through effective lifestyle interventions. …”
    Get full text
    Article